News | May 17, 2007

ACC TEST - FDA Advisory Committee Unanimously Votes in Favor of Acambis' Smallpox Vaccine

May 18, 2007 — Acambis plc (Acambis), a biotechnology company targeting infectious diseases with novel vaccines, announces that the Vaccines and Related Biological Products Advisory Committee of the FDA voted unanimously that Acambis' smallpox vaccine, ACAM2000, is both safe and efficacious.

The Advisory Committee was asked to review whether the efficacy and safety data were sufficient to support the use of ACAM2000 in situations where it is determined that there is high risk of exposure to smallpox virus. At a meeting held in Gaithersburg, MD, the panel voted 11-0 in favor on both the safety and efficacy of ACAM2000.

The Advisory Committee provides the FDA with independent, non-binding advice from outside experts on issues related to vaccines and biological products. While the Committee provides recommendations to the Agency, the FDA makes all final decisions regarding licensure.

To date, Acambis has supplied 192.5 million doses of ACAM2000 to the U.S. Centers for Disease Control and Prevention (CDC) for the Strategic National Stockpile (SNS) under an FDA Investigational New Drug applicaton. The CDC procured ACAM2000 as part of the Government's policy, adopted after the events of 9/11, to establish a smallpox vaccine stockpile large enough to provide a dose for every man, woman and child in the US.

Acambis developed ACAM2000 under contracts with the CDC and conducted clinical development of the vaccine in parallel with the manufacturing program. ACAM2000 was derived from the smallpox vaccine used during the global eradication programme and is manufactured using modern cell-culture techniques. It is intended to be used for protection of persons determined to be at high risk for smallpox infection, including vaccination of military personnel being deployed to certain regions.

For more information visit www.acambis.com.

Related Content

Ingenia Ambition X 1.5T MR. This innovation is the latest advance in the Ingenia MRI portfolio, which comprises fully-digital MRI systems, healthcare informatics and a range of maintenance and life cycle services for integrated solutions that empower a faster, smarter, and simpler path to enabling a confident diagnosis
News | Magnetic Resonance Imaging (MRI) | September 14, 2018
Philips, a global leader in health technology, launched the Ingenia Ambition X 1.5T MR.
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Videos | Radiomics | August 09, 2018
A discussion with Martin Vallieres, Ph.D., post-doctoral fellow at McGill University, Montreal, Canada.
Gary D. Luker Named Editor of Radiology: Imaging Cancer

Image courtesy of University of Michigan Medical School

News | Oncology Diagnostics | August 06, 2018
The Board of Directors of the Radiological Society of North America (RSNA) announced that Gary D. Luker, M.D., will...
Videos | Digital Radiography (DR) | August 03, 2018
Sheila Sferrella, president of Regents Health Resources and Bill Finerfrock, president of Capitol Associates, discuss
Videos | AAPM | August 03, 2018
Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke Un...
New Regulatory Approvals Driving Research and Development Dollars in Medical Imaging Artificial Intelligence
News | Artificial Intelligence | August 01, 2018
Medical imaging has become the bellwether for the application of artificial intelligence (AI) technologies, especially...
Videos | Artificial Intelligence | August 01, 2018
A discussion with Steve Jiang, Ph.D., director of the medical...
Sectra radiation dose monitoring software can help manage radiation dose from multiple medical imaging modalities.
News | Radiation Dose Management | July 25, 2018
July 25, 2018 – Sectra will install its cloud-based,...
Magseed magnetic marker
Technology | Tumor Tracking Systems | July 20, 2018
Endomag, the surgical guidance company, received 510(k) clearance from the U.S.